<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652522</url>
  </required_header>
  <id_info>
    <org_study_id>AF06003AF</org_study_id>
    <nct_id>NCT00652522</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation Management in Congestive Heart Failure With Ablation</brief_title>
  <acronym>AMICA</acronym>
  <official_title>Atrial Fibrillation Management in Congestive Heart Failure With Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the purpose of the study to show the benefit of the endocardial catheter ablation by&#xD;
      pulmonary vein isolation in patients with persistent or longstanding persistent atrial&#xD;
      fibrillation, low LVEF and requiring ICD or CRT-D therapy compared to the best medical&#xD;
      treatment with antiarrhythmic drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation is the most common sustained cardiac arrhythmia affecting 5% of people&#xD;
      older than 65 years. It is associated with a 5 times increase of the risk of stroke in&#xD;
      patients who are not receiving anticoagulant therapy and a doubling of the rate of death in&#xD;
      all patients.&#xD;
&#xD;
      Congestive heart failure (CHF) and atrial fibrillation (AF) often co-exist, where one&#xD;
      condition is promoting the development of the other and worsens its condition.&#xD;
&#xD;
      It is the purpose of the study to show the benefit of the endocardial catheter ablation by&#xD;
      pulmonary vein isolation in patients with persistent (for a minimum of 1 week to a maximum of&#xD;
      1 year duration) or longstanding persistent (for a minimum of 1 year to a maximum of 4 years)&#xD;
      atrial fibrillation, low LVEF (&lt;=35%) and requiring ICD or CRT-D therapy compared to the best&#xD;
      medical treatment with antiarrhythmic drugs.&#xD;
&#xD;
      Patients meeting the inclusion and exclusion criteria will be randomized in a 1:1 fashion in&#xD;
      an unblinded, parallel arm treatment format to either drug therapy (directed at rate or&#xD;
      rhythm control) or catheter ablation.&#xD;
&#xD;
      All therapies will be established and optimized in a 3 month treatment initiation phase&#xD;
      (Blanking Period) starting with randomization. For all morbidity and mortality end-points,&#xD;
      intention-to-treat analysis will begin at randomization. Efficacy with respect to AF&#xD;
      treatment will be established for long-term follow up beginning after 3-month initiation&#xD;
      phase.&#xD;
&#xD;
      Improvement of LVEF within 12 month is the primary endpoint of this study. The transthoracic&#xD;
      echocardiographic (TTE) assessment at enrollment, discharge and 12 months follow-up follows a&#xD;
      standardized protocol. The assessments are analyzed, calculated and expressed by an&#xD;
      independent Core Lab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">July 13, 2017</completion_date>
  <primary_completion_date type="Actual">July 13, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) by transthoracic echocardiography (TTE)</measure>
    <time_frame>12months</time_frame>
    <description>evaluated by Core Lab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of atrial tachyarrhythmia</measure>
    <time_frame>9 months</time_frame>
    <description>diagnosed by daily ECG via ECG-recording card</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity in 6 min walk test</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>assessed by Minnesota Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF burden</measure>
    <time_frame>9 months</time_frame>
    <description>assessed by ICD/CRT-D device memory in SJM devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adequate and inadequate ICD interventions</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <condition>ICD</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best Medical Treatment, ICD/CRT implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AF Ablation, ICD/CRT implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD/CRT implant</intervention_name>
    <description>Implantation of a ICD/ CRT device if not yet implanted</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>ICDs/ CRT-Ds: All St. Jude Medical device</other_name>
    <other_name>RA, RV and LV leads: St. Jude Medical CE-marked leads recommended</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AF ablation</intervention_name>
    <description>Atrial Fibrillation ablation by pulmonary vein isolation</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Catheters: St. Jude Medical CE-marked catheters recommended</other_name>
    <other_name>NavX system for 3D mapping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Medical Treatment</intervention_name>
    <description>Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Conventional rate or rhythm control according valid guidelines</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having signed and dated Patient Informed Consent&#xD;
&#xD;
          -  Having an indication for ICD or CRT-D therapy as indicated by current valid guidelines&#xD;
             or having been implanted with an ICD or CRT-D&#xD;
&#xD;
          -  Symptomatic atrial fibrillation (persistent AF (for a minimum of 1 week to a maximum&#xD;
             of 1 year) or longstanding persistent AF (for a minimum of 1 year to a maximum of 4&#xD;
             years)) irrespective of the duration of paroxysmal AF&#xD;
&#xD;
          -  Ejection fraction ≤ 35% as assessed by transthoracic echocardiography&#xD;
&#xD;
          -  Left atrial diameter of less than 60 mm in parasternal diameter during transthoracic&#xD;
             echocardiographic study&#xD;
&#xD;
          -  ECG documentation of atrial fibrillation (ECG, Holter, event recorders, etc) related&#xD;
             to symptomatic episodes&#xD;
&#xD;
          -  Having typical symptoms of heart failure NYHA II - III&#xD;
&#xD;
          -  Patients &gt; 30 days under optimal medical treatment for heart failure and CRT therapy&#xD;
             in case of a pre-implanted CRT-D device&#xD;
&#xD;
          -  Age 18 - 75 years&#xD;
&#xD;
          -  Willing to participate in randomized trial&#xD;
&#xD;
          -  Willing and able to participate in 12 months follow-up period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Longstanding persistent (&gt; 4 years history) or paroxysmal atrial fibrillation&#xD;
&#xD;
          -  Having a previously implanted pacemaker&#xD;
&#xD;
          -  Having underlying valvular heart disease unless the disease has been corrected&#xD;
&#xD;
          -  Patients with acute myocardial infarction&#xD;
&#xD;
          -  Patients who have had previous pulmonary vein isolation procedures&#xD;
&#xD;
          -  Patients with atrial fibrillation secondary to a reversible cause&#xD;
&#xD;
          -  Known presence of intracardiac or other thrombi&#xD;
&#xD;
          -  Pregnant females or those of child bearing potential who have not had a negative&#xD;
             pregnancy test within 48 hours before treatment&#xD;
&#xD;
          -  Patients with other medical condition (i.e., cancer, alcoholism, drug abuse) that may&#xD;
             cause the patient to be non-compliant with the protocol, confound the data&#xD;
             interpretation or is associated with limited life-expectancy (i.e., less than one&#xD;
             year)&#xD;
&#xD;
          -  History of bleeding diathesis or suspected pro-coagulant state&#xD;
&#xD;
          -  Contraindication to anticoagulation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Kuck, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik St. Georg - Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz- und Gefaesszentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg - Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik gGmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin - Charité Campus Virchow-Klinikum (CVK)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg GmbH / UKE</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ruprecht-Karls-Universität Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt GmbH</name>
      <address>
        <city>Ingolstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern der Ludwig-Maximilians-Universität</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum am Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Adolf-Stift Reinbek</name>
      <address>
        <city>Reinbek</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF ablation</keyword>
  <keyword>Pulmonary vein isolation(PVI)</keyword>
  <keyword>reduced LV ejection fraction</keyword>
  <keyword>symptomatic atrial fibrillation</keyword>
  <keyword>persistent AF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

